GlassScriptPhysician profile
James H Crews
NPI 1154374957
$1,192.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $223 · 2021: $249 · 2022: $398 · 2023: $52.78 · 2024: $81.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.33 | 2019-2022 | |
| Coopersurgical, INC. | $214.29 | 2019-2021 | |
| Davol INC. | $136.71 | 2022 | |
| Intuitive Surgical, INC. | $80.00 | 2022 | |
| Innovation Technologies INC | $68.02 | 2024 | Irrisept |
| Mayne Pharma Commercial LLC | $63.28 | 2021-2023 | |
| Conmed Corporation | $50.00 | 2022 | |
| Pfizer INC. | $27.56 | 2019-2022 | |
| Myovant Sciences INC. | $25.44 | 2021-2022 | |
| Baxter Healthcare | $22.30 | 2021 | |
| Applied Medical Resources Corporation | $15.39 | 2019 | |
| Shield Therapeutics INC | $15.20 | 2022 | |
| Amgen INC. | $15.17 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.90 | 2020 | |
| Sumitomo Pharma America, INC. | $14.85 | 2023 | Gemtesa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $13.42 | 2024 | |
| Exeltis, USA INC. | $12.00 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $11.83 | 2019 | |
| Boston Scientific Corporation | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Crews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.